Lifeward opened lower at $5.71, compared with its previous close of $5.76. In the last trading session, the stock traded between $5.54 and $5.77. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in Lifeward is now worth
$ 6.37
Resulting in a loss of
$ 93.63 (93.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.04 (-0.61%)
Day High
$5.77
Day Low
$5.54
Day Open
$5.71
Prev Close
$5.76
Volume
5,443
1W Return
-5.53%
1M Return
-10.76%
3M Return
-24.52%
6M Return
-10.55%
1Y Return
-9.76%
Fundamentals
Market Cap ($ Mn)
16
PE Ratio
-
PB Ratio
1.73
PEG Ratio
-
ROE
-135.33%
ROCE
-120.75%
EPS (TTM)
$-4.07
Investment Returns
1 Week
-5.53%
1 Month
-10.76%
3 Months
-24.52%
6 Months
-10.55%
9 Months
-11.77%
Financials
Quarterly
All values in $ Mn
5.0
Mar 25
5.7
Jun 25
6.2
Sep 25
5.1
Dec 25
3.9
Mar 26
6.6
Jun 26
Updates
9Oct
Lifeward confirms Rami Aviram will not assume CFO role
Rami Aviram will not assume the Chief Financial Officer role at Lifeward Limited. Josh Hexter continues as interim Principal Financial Officer and Principal Accounting Officer. Notification issued via SEC filing with no additional financial metrics disclosed.
Lifeward appoints Josh Hexter as interim CEO effective September 1, 2026. Rami Aviram named CFO effective November 1, 2026. Q2 2026 revenue rose 16% YoY to $6.6 million. AlterG revenue grew 25%, outpacing ReWalk's 13% growth. Mark Grant transitions to consultant role until September 30.
Lifeward Ltd reported Q2FY26 revenue of $6.623 million, beating estimates of $6.530 million. Adjusted EPS of $(1.46) missed the consensus estimate of $(1.34). GAAP net loss widened to $11.5 million due to non-cash charges, while gross margin contracted to 41%.
3mo ago
8Jul
Lifeward secures $5.6M in strategic financing to fund expansion
Lifeward Ltd. closed an initial $5.6 million tranche of senior secured convertible notes on July 6, 2026, with a further $5.6 million committed upon achieving milestones like a 150% rise in ReWalk sales or a share price of $13.80. This deal is part of a larger strategic framework with Oramed Pharmaceuticals offering access to $47 million. The funds will support the expansion of the company's reimbursement-backed distribution model and product portfolio.
